8-K: Health Catalyst Announces Q3 2024 Results, Acquisition of Intraprise Health, and New Board Member

Health Catalyst reported strong Q3 2024 financial results, announced the acquisition of Intraprise Health, and appointed Dr. Jill Hoggard Green to its board of directors.

Summary

• Health Catalyst reported a total revenue of $76.4 million and an adjusted EBITDA of $7.3 million for the third quarter of 2024, exceeding the mid-point of their guidance.
• The company's net loss for the quarter was $14.7 million.
• Health Catalyst has raised its full-year 2024 Adjusted EBITDA guidance by $1 million.
• They expect full-year revenue to be between $305 million and $311 million, and Adjusted EBITDA between $25 million and $27 million.
• Health Catalyst has entered into an agreement to acquire Intraprise Health for approximately $43 million, with the deal expected to close by the end of 2024.
• The acquisition will be funded with a mix of cash and approximately 2,200,490 shares of Health Catalyst common stock.
• Dr. Jill Hoggard Green has been appointed to the board of directors, effective December 1, 2024, and will also serve on the Compensation Committee.
• Dr. Hoggard Green will receive a pro-rated $45,000 annual cash retainer for board service and a pro-rated $7,500 cash retainer for Compensation Committee service, along with an initial award of restricted stock units valued at $225,000.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, a strategic acquisition, and a new board member. The company exceeded expectations for the quarter and raised guidance, indicating a positive trajectory. However, the net loss and modest revenue growth temper the overall sentiment slightly.

Positives

• The company exceeded the mid-point of its quarterly guidance for both total revenue and Adjusted EBITDA.
• Adjusted EBITDA saw a significant year-over-year increase of 266%.
• The company raised its full-year Adjusted EBITDA guidance by $1 million.
• The acquisition of Intraprise Health is expected to enhance Health Catalyst's cybersecurity offerings.
• The appointment of Dr. Jill Hoggard Green to the board brings significant healthcare leadership experience.
• The company expects a return to double-digit topline growth in 2025.

Negatives

• The company reported a net loss of $14.7 million for the third quarter of 2024.
• The company's total revenue growth was only 3% year-over-year.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including macroeconomic conditions and the integration of Intraprise Health.
• There are risks related to closing the acquisition of Intraprise Health.
• The company faces risks related to changes in laws and regulations, market conditions, and the loss of key clients or partners.
• The company's ability to recruit and retain qualified team members is a risk factor.

Future Outlook

Health Catalyst anticipates a return to double-digit topline growth in 2025 and expects approximately 50% Adjusted EBITDA growth in 2025. The company also expects the acquisition of Intraprise Health to close by the end of 2024.

Management Comments

• Dan Burton, CEO of Health Catalyst, stated that he is pleased with the strong financial results, which exceeded the mid-point of their quarterly guidance.
• Dan Burton also mentioned that the company is encouraged with their bookings results through Q3 2024 and is excited to continue this momentum in Q4.
• Dan Burton noted that the company is raising its Adjusted EBITDA guidance by $1 million for 2024, which is a testament to their commitment to financial discipline, operating leverage, and profitable growth.
• Dan Burton said that the addition of Intraprise will help fortify the support they provide healthcare leaders, specifically addressing the costs associated with risk management.
• George Pappas, CEO of Intraprise Health, stated that Health Catalyst's ecosystem is well positioned to help power additional foundational capabilities within their offerings.
• Dave Ross, Chief Product Officer and Chief Technology Officer of Health Catalyst, said that folding in Intraprise's generative AI will have a significant impact on their clients' data-driven efforts.

Industry Context

The acquisition of Intraprise Health reflects a growing trend in the healthcare industry to address cybersecurity risks, which are becoming increasingly prevalent. Health Catalyst is positioning itself to offer a more comprehensive solution to its clients by integrating cybersecurity services with its existing data and analytics platform. This move aligns with the industry's focus on data security and risk management.

Comparison to Industry Standards

• Health Catalyst's Q3 2024 revenue growth of 3% year-over-year is modest compared to some high-growth SaaS companies in the healthcare technology sector, which can see growth rates in the double digits.
• However, the 266% year-over-year increase in Adjusted EBITDA suggests improved operational efficiency and profitability, which is a positive sign compared to industry peers that may be struggling with profitability.
• The acquisition of Intraprise Health is a strategic move to enhance their cybersecurity offerings, which is a growing area of focus for healthcare providers and a competitive differentiator.
• The appointment of Dr. Jill Hoggard Green, a nationally recognized healthcare executive, to the board of directors is a positive move that brings significant industry expertise and credibility to the company, which is comparable to other companies that seek to add industry leaders to their boards.

Management Changes

Related Party Transactions

• The Queens Health System, where Dr. Hoggard Green was previously CEO, is a client of Health Catalyst, with payments of approximately $5.4 million in 2023 and $9.9 million in the first nine months of 2024.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and the strategic acquisition.
• Employees may benefit from the company's growth and expansion.
• Customers will gain access to enhanced cybersecurity offerings.
• Suppliers and creditors will likely see continued business with the company.

Next Steps

• The company will close the acquisition of Intraprise Health by the end of 2024.
• Dr. Jill Hoggard Green will join the board of directors and Compensation Committee on December 1, 2024.
• The company will continue to focus on driving profitable growth and scaling its operations.
• The company will host a conference call to review the results on November 6, 2024.

Key Dates

Keywords

Health Catalyst, Intraprise Health, Cybersecurity, Healthcare Analytics, Financial Results, Acquisition, Board of Directors, Adjusted EBITDA, Revenue, Data Analytics